Marker Therapeutics (MRKR) Misses Q1 EPS by 2c

May 12, 2021 4:32 PM EDT
Get Alerts MRKR Hot Sheet
Price: $3.27 +1.24%

EPS Growth %: -14.3%

Today's EPS Names:
XYF, LEN, More
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Marker Therapeutics (NASDAQ: MRKR) reported Q1 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14).

"We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline," said Peter L. Hoang, President & CEO of Marker Therapeutics. "In addition, we continue to make strong progress on both the clinical and manufacturing fronts. In March, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia, or AML, and continue to activate clinical sites. In parallel, we continue to optimize the MT-401 cell therapy manufacturing process, which we believe could result in an increase in the number of T cells available for patient administration—among other benefits—as we prepare to operationalize our new in-house cGMP facility in the first half of the year."

For earnings history and earnings-related data on Marker Therapeutics (MRKR) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities